Pharsight

1. Cambia patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8097651	ASSERTIO	Diclofenac formulations and methods of use	Jun, 2026 (2 years from now)
US7759394	ASSERTIO	Diclofenac formulations and methods of use	Jun, 2026 (2 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8927604	ASSERTIO	Diclofenac formulations and methods of use	Jun, 2026 (2 years from now)
US9827197	ASSERTIO	Diclofenac formulations and methods of use	Jun, 2026 (2 years from now)

Drugs and Companies using DICLOFENAC POTASSIUM ingredient

Market Authorisation Date: 17 June, 2009

Treatment: Acute treatment of migraine attacks with or without aura in adults

Dosage: FOR SOLUTION;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
50 mg	24 Jan, 2011	1		16 Jun, 2026	Extinguished

Strength	Dosage	Availability
50MG	FOR SOLUTION;ORAL	Prescription

CAMBIA family patents

2. Zipsor patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8623920	ASSERTIO	Method of treating post-surgical acute pain	Feb, 2029 (5 years from now)
US7662858	ASSERTIO	Method of treating post-surgical acute pain	Feb, 2029 (5 years from now)
US9561200	ASSERTIO	Method of treating post-surgical acute pain	Feb, 2029 (5 years from now)
US8110606	ASSERTIO	Method of treating post-surgical acute pain	Feb, 2029 (5 years from now)
US7884095	ASSERTIO	Method of treating post-surgical acute pain	Feb, 2029 (5 years from now)
US7939518	ASSERTIO	Method of treating post-surgical acute pain	Feb, 2029 (5 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Patient Population (NPP)	May 25, 2024

Drugs and Companies using DICLOFENAC POTASSIUM ingredient

Market Authorisation Date: 16 June, 2009

Treatment: Diclofenac potassium for relief of mild to moderate acute pain; Nonsteroidal anti-inflammatory drug indicated for relief of mild to moderate acute pain

Dosage: CAPSULE;ORAL